Deepa Jhaveri, DPM
Podiatrist · Burlington, MANPI 1477549350
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,785 of the $4,630 with a category attached, or 60.2%. Mimedx Group, Inc. accounts for 65.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $3,271 and has fallen 80.5% since, to $638 in 2025.
Across 27 payments — averaging $171.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$3K
- Amgen$354
- Paratek Pharmaceuticals, Inc.$350
- Kerecis Limited$269
- Averitas Pharma Inc.$178
- Stryker$164
- plus $296 from 3 others
What the payments were for
- Travel & lodging$1,84540%
- Food & beverage$2,78560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 10 | $3,020 |
| Amgen(2 entities) | 4 | $354 |
| Paratek Pharmaceuticals, Inc. | 3 | $350 |
| Kerecis Limited | 2 | $269 |
| Averitas Pharma Inc. | 3 | $178 |
| Stryker | 1 | $164 |
| Smith+Nephew | 2 | $113 |
| GRT US Holding, Inc. | 1 | $106 |
| Organogenesis Inc. | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$536
- Kerecis Omega3 Marigen$405
- NUZYRA$350
- Qutenza$227
- LIMFLOW SYSTEM$164
- Kerecis Omega3 SurgiClose$135
- Kerecis Omega3 GraftGuide$135
- Kerecis GraftGuide$134
- KRYSTEXXA$116
How this compares
$4,630 in reported general payments places this provider in the 85th percentile of 179 podiatrist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 28 | $408 |
| Ciclopirox | 18 | $381 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $210 |
| Mupirocin | 13 | $145 |
| Terbinafine Hcl | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Burlington
- Mazin SadikBurlington$5K
- Pasquale CancelliereSomerville$374K
- Michael TheodoulouSomerville$210K
- Sara Rose-SauldWaltham$92K
- Jonathan KaplanWellesley$56K
- Thanh DinhBoston$48K
- Melissa RicciMilton$46K
- Jeffrey PantanoMilton$46K
- Barry RosenblumBoston$43K
- Louis DecaroWest Hatfield$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.